Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study
-
- Kinoshita Yoshikazu
- Department of Gastroenterology and Hepatology, Shimane University, School of Medicine, Japan
-
- Hongo Michio
- Department of Medicine, Kurokawa Hospital, Japan
-
- Kusano Motoyasu
- Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Japan
-
- Furuhata Yoshinori
- Eisai Co., Ltd., Japan
-
- Miyagishi Hideaki
- Eisai Co., Ltd., Japan
-
- Ikeuchi Satoshi
- Eisai Co., Ltd., Japan
この論文をさがす
説明
<p>Objective To investigate the effect of twice-daily rabeprazole doses on health-related quality of life in refractory patients. </p><p>Methods and Patients Reflux esophagitis patients with an insufficient response to once-daily proton pump inhibitor therapy (Los Angeles Classification grade A-D) received rabeprazole 10 mg or 20 mg twice daily for 8 weeks. The health-related quality of life (SF-8™) and symptoms, using the Frequency Scale for the Symptoms of Gastroesophageal reflux disease, were evaluated before treatment and at weeks 4 and 8. Endoscopy was performed at baseline and at weeks 8 and 32 where possible. The rabeprazole dose was determined by the attending physician. </p><p>Results There were 1,796 patients analyzed for the efficacy of the twice-daily treatment. Of these cases, 1,462 were treated with rabeprazole 10 mg twice daily, and 334 were treated with rabeprazole 20 mg twice daily. The factors that affected the selection of the twice-daily rabeprazole dose by physicians were evaluated, and as expected, "endoscopic findings when treatment was started" had a strong effect on the selection of the rabeprazole dose. With both regimens, health-related quality of life and subjective symptoms were significantly improved at weeks 4 and 8 compared to baseline (p<0.001). The recurrence rate of erosive esophagitis at week 32 was 9.7% in rabeprazole twice daily-treated patients and 28.4% in proton pump inhibitor (PPI) once daily-treated patients. Both regimens were well tolerated. </p><p>Conclusion Twice-daily treatment with rabeprazole improved the subjective symptoms and health-related quality of life in patients with refractory reflux esophagitis more effectively than the standard once-daily dose. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 56 (10), 1131-1139, 2017
一般社団法人 日本内科学会